Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Introduction and Identifying Predictive Biomarkers

August 20th 2020

Repotrectinib Elicits Encouraging Response Rates in ROS1- and NTRK-Driven Tumors

August 19th 2020

Treatment with repotrectinib resulted in favorable responses in patients with ROS1- or NTRK-driven tumors, regardless of prior treatment with TKIs, according to interim data from the phase 2 TRIDENT-1 trial.

Dr. Bunn on Targeting HER3 in NSCLC

August 18th 2020

Paul A. Bunn, Jr MD, discusses potentially targeting HER3 in non–small cell lung cancer.

FDA Grants Durvalumab Priority Review for Fixed-Dose Use in NSCLC and Bladder Cancer

August 18th 2020

The FDA has granted a priority review designation to a supplemental biologics license application for a new 4-week, fixed-dose regimen as treatment in approved indications of non–small cell lung cancer and bladder cancer.

FDA Grants Trilaciclib Priority Review for Small Cell Lung Cancer

August 17th 2020

The FDA has granted a priority review designation to a new drug application (NDA) for trilaciclib for the treatment of patients with small cell lung cancer (SCLC) who are being treated with chemotherapy.

Future of ALK-rearranged mNSCLC

August 17th 2020

Testing for ALK Rearrangements in mNSCLC

August 17th 2020

Subsequent Lines of Therapy in ALK-rearranged mNSCLC

August 17th 2020

Updates Informing the Management of ALK-rearranged mNSCLC

August 17th 2020

Updates Informing the Management of NTRK+ NSCLC

August 17th 2020

NTRK Gene Fusions in NSCLC

August 17th 2020

Future Directions for ROS1 rearranged mNSCLC

August 17th 2020

ALKA-372-001, STARTRK-1, and STARTRK-2 Trials

August 17th 2020

Current Management of ROS1 rearranged NSCLC

August 17th 2020

ROS1 Rearrangements in mNSCLC

August 17th 2020

Molecular Testing for NSCLC

August 17th 2020

Overview of Rare Driver Alterations in NSCLC

August 17th 2020

Chasing a Cure in Lung Cancer: Kris Urges Pushing Forward in COVID-19 Era

August 16th 2020

In an interview with OncLive, Mark G. Kris, MD discusses how the treatment of patients with metastatic lung cancer today bears scant resemblance to what it was when he entered the field 4 decades ago.

Experts Debate the Significance of ADAURA Data With Adjuvant Osimertinib in EGFR+ NSCLC

August 14th 2020

The phase 3 ADAURA trial continues to generate a lot conversation, debate, and excitement in the lung cancer community after results showed that adjuvant osimertinib showed a statistically significant improvement in disease-free survival in patients with stage IB-IIIA EGFR-positive non–small cell lung cancer, making it the first agent to do so in the space.

Sequential Afatinib and Osimertinib Shows Continued OS Benefit in EGFR+ NSCLC

August 10th 2020

Treatment with afatinib followed by osimertinib resulted in a median overall survival benefit of almost 4 years in US patients with EGFR T790M–positive non–small cell lung cancer in the real-world setting.